Challenges and advances towards the rational design of mRNA vaccines
- PMID: 24138818
- DOI: 10.1016/j.molmed.2013.09.002
Challenges and advances towards the rational design of mRNA vaccines
Abstract
In recent years, mRNA vaccines have emerged as a safe and potent approach for the induction of cellular immune responses. Whereas initial studies were limited to the ex vivo loading of dendritic cells (DCs) with antigen-encoding mRNA, recent progress has led to the development of improved mRNA vaccines that enable direct in vivo targeting of DCs. Although preclinical studies demonstrated their potency in inducing antitumor immunity, several bottlenecks hinder the broader application of mRNA vaccines. In this review, we discuss the challenges associated with mRNA-based vaccination strategies, the technological advances that have been made to overcome these limitations, and the hurdles that remain to be tackled for the development of an optimal mRNA vaccine.
Keywords: cellular immunity; cytotoxic T cells; dendritic cell; mRNA; nucleic acid-based vaccines; vaccination.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.Methods Mol Biol. 2008;423:155-63. doi: 10.1007/978-1-59745-194-9_10. Methods Mol Biol. 2008. PMID: 18370196
-
The ReNAissanCe of mRNA-based cancer therapy.Expert Rev Vaccines. 2015 Feb;14(2):235-51. doi: 10.1586/14760584.2015.957685. Epub 2014 Sep 29. Expert Rev Vaccines. 2015. PMID: 25263094 Review.
-
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417017
-
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.J Immunother. 2011 Jan;34(1):1-15. doi: 10.1097/CJI.0b013e3181f7dbe8. J Immunother. 2011. PMID: 21150709
-
mRNA Cancer Vaccines.Recent Results Cancer Res. 2016;209:61-85. doi: 10.1007/978-3-319-42934-2_5. Recent Results Cancer Res. 2016. PMID: 28101688 Review.
Cited by
-
[COVID-19, management, therapeutic and vaccine approaches].Actual Pharm. 2020 Oct;59(599):27-33. doi: 10.1016/j.actpha.2020.08.007. Epub 2020 Aug 21. Actual Pharm. 2020. PMID: 32863556 Free PMC article. French.
-
mRNA vaccines for COVID-19 and diverse diseases.J Control Release. 2022 May;345:314-333. doi: 10.1016/j.jconrel.2022.03.032. Epub 2022 Mar 21. J Control Release. 2022. PMID: 35331783 Free PMC article. Review.
-
mRNA vaccines for cancer immunotherapy.Front Immunol. 2022 Dec 14;13:1029069. doi: 10.3389/fimmu.2022.1029069. eCollection 2022. Front Immunol. 2022. PMID: 36591226 Free PMC article. Review.
-
The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels.Immunol Res. 2022 Dec;70(6):800-810. doi: 10.1007/s12026-022-09309-5. Epub 2022 Aug 18. Immunol Res. 2022. PMID: 35978253 Free PMC article.
-
Biomedical applications of mRNA nanomedicine.Nano Res. 2018 Oct;11(10):5281-5309. doi: 10.1007/s12274-018-2146-1. Epub 2018 Jul 27. Nano Res. 2018. PMID: 31007865 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical